Barth Roos E, Wensing Annemarie M, Tempelman Hugo A, Moraba Robert, Schuurman Rob, Hoepelman Andy I
Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands.
AIDS. 2008 Oct 18;22(16):2210-2. doi: 10.1097/QAD.0b013e328313bf87.
In a large cohort in rural South Africa, 73% of subtype-C-infected patients initiating highly active antiretroviral therapy achieved viral suppression. In patients with subsequent virological failure, an unexpected, rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated mutations was observed, whereas no thymidine analogue-associated mutations emerged. It appeared that several patients had drug-associated mutations prior to starting antiretrovirals, suggesting that transmission of resistance may have contributed to the accumulation of nonnucleoside reverse transcriptase inhibitor-mutations. Importantly, monitoring of HIV-RNA and prompt switch of treatment may prevent development of thymidine analogue-associated mutations.
在南非农村的一个大型队列中,开始接受高效抗逆转录病毒治疗的C型亚型感染患者中有73%实现了病毒抑制。在随后出现病毒学失败的患者中,观察到非核苷类逆转录酶抑制剂相关突变意外迅速积累,而未出现与胸苷类似物相关的突变。似乎有几名患者在开始抗逆转录病毒治疗之前就已经存在药物相关突变,这表明耐药性的传播可能导致了非核苷类逆转录酶抑制剂突变的积累。重要的是,监测HIV-RNA并及时更换治疗方案可能会预防与胸苷类似物相关的突变的发生。